BSF Enterprise PLC (LSE:BSFA) has confirmed that it has mutually agreed with counterparties to cancel its proposed £15 million equity fundraising and related capital reorganisation, effectively unwinding the agreements linked to the transaction. However, a previously announced £300,000 convertible loan note will remain in place and has been extended by a further 12 months, with investors retaining the option to convert their holdings at the price set in BSF’s next fundraising round.
In the wake of the cancelled transaction, the company has begun engaging with alternative investors to secure new funding both at the group level and within its subsidiaries, Lab-grown Leather Ltd and Kerato Ltd. Management said it aims to complete a replacement financing round in the coming weeks on terms that may prove more favourable, which would be important for advancing its tissue-engineering strategy and sustaining development across its sustainable materials and biotechnology initiatives.
The company’s outlook remains constrained by persistent losses and ongoing cash burn, which continue to weigh heavily on financial performance. Technical indicators also point to a sustained downward trend with negative momentum signals. While BSF maintains a debt-free balance sheet that offers some financial stability, valuation measures remain limited given the company’s loss-making position and the absence of a dividend yield.
More about BSF Enterprise PLC
BSF Enterprise PLC is a biotechnology company focused on the development and commercialisation of tissue-engineered products. Its work includes lab-grown leather, cultivated meat and corneal repair technologies. Through its proprietary scaffold-free platform, the company aims to address growing global demand for sustainable and environmentally responsible alternatives to conventional materials across both consumer and medical markets.
Leave a Reply